According to Zhitong Finance App News, Innox (688710.SH) released its report for the third quarter of 2026. The company achieved operating income of 786 million yuan in the first three quarters, an increase of 37.80%; net profit attributable to shareholders of listed companies was 94.013,700 yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 852.78 million yuan; and basic earnings per share were 0.67 yuan.

During the reporting period, in the face of the new market pattern brought about by changes in the investment and financing environment in the biomedical industry, the company seized opportunities to pick up demand for innovative drugs and continued to consolidate and enhance its core competitiveness. In the first three quarters of 2026, the amount of new orders signed by the company was 2,218 billion yuan, an increase of 183.27% over the previous year; by the end of the reporting period, the company had orders of 2,625 billion yuan, an increase of 110.34% over the end of 2025. The rapid increase in new signatures and on-hand orders fully reflects the simultaneous increase in market demand and the company's ability to obtain orders. In-hand order reserves are sufficient, injecting strong momentum into the company's high-quality and sustainable development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.